The article “The devil is in the divisional: an analysis of divisional patents, deadlines, declarations and suggestions for future practice” by Mieke Filler provides a comprehensive analysis of the strategic use of divisional patents in the pharmaceutical sector to delay generic and biosimilar market entry. Key Points Citations:[1] https://academic.oup.com/jiplp/advance-article/doi/10.1093/jiplp/jpae046/7693785[2] https://www.bakerbotts.com/thought-leadership/publications/2021/october/on-the-interface-of-intellectual-property-and-antitrust[3] https://www.bakerbotts.com/~/media/files/thought-leadership/publications/2021/october/medicines-for-europe-position-paper-on-divisional-patents-mar-20211.pdf?hash=82CB8F9CFD49A2B2099711E363E79DD6E00B46F9&la=en[4] https://www.aipla.org/list/innovate-articles/revisiting-divisional-patent-applications-the-plurality-of-inventions-debate-in-india[5] https://www.iam-media.com/review/the-patent-prosecution-review/2024/article/israel-deep-dive-national-prosecution-processes[6] https://www.managingip.com/article/2c6zuwss3s78xp9byrr40/expert-analysis/special-focus/divisional-patent-applications-in-india-the-power-of-a-comma
